# Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

> **NCT00498654** · PHASE2 · COMPLETED · sponsor: **Avant Immunotherapeutics** · enrollment: 180 (estimated)

## Conditions studied

- Typhoid Fever

## Interventions

- **BIOLOGICAL:** Ty800 (Salmonella typhi) Oral Vaccine

## Key facts

- **NCT ID:** NCT00498654
- **Lead sponsor:** Avant Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2007-10
- **Final completion:** 2008-06
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2008-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498654, "Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00498654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*